Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
We analysed viral kinetics from a 2-day treatment with BILN 2061, a serine protease inhibitor of hepatitis C virus, in patients chronically infected with genotype 1 hepatitis C virus. The efficiency (E), describing inhibition of viral production, was above 99.45% in all patients with minor or moderate fibrosis receiving doses of 200mg and 500 mg twice daily and larger than in previous studies for interferon-based treatments. However, epsilon was slightly smaller in patients with cirrhosis given 200mg and markedly smaller in patients given 25 mg. Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments.
Herrmann
Eva
E
Medizinische Klinik und Poliklinik, Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Eva.Herrmann@Uniklinikum-Saarland.de
Zeuzem
Stefan
S
Sarrazin
Christoph
C
Hinrichsen
Holger
H
Benhamou
Yves
Y
Manns
Michael P
MP
Reiser
Markus
M
Reesink
Henk
H
Calleja
José L
JL
Forns
Xavier
X
Steinmann
Gerhard G
GG
Nehmiz
Gerhard
G
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D019540:Area Under Curve; D002219:Carbamates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007700:Kinetics; D047028:Macrocyclic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011804:Quinolines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood*; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000998:Antiviral Agents; C479555:BILN 2061; D002219:Carbamates; D016898:Interferon-alpha; D047028:Macrocyclic Compounds; D011804:Quinolines; D012367:RNA, Viral; D015842:Serine Proteinase Inhibitors; D013844:Thiazoles